British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
British Columbia Centre on Substance Use, British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
J Subst Abuse Treat. 2018 Nov;94:41-46. doi: 10.1016/j.jsat.2018.08.009. Epub 2018 Aug 23.
Methadone maintenance therapy (MMT) continues to be a key treatment for opioid use disorder, although premature discontinuation of MMT can increase risk for overdose and other severe harms. We examined sociodemographic characteristics, substance use patterns and social-structural exposures associated with MMT discontinuation among a cohort of people who use drugs (PWUD) in Vancouver, Canada.
Data were derived from VIDUS and ACCESS, prospective cohorts of PWUD in Vancouver, Canada. The outcome of interest was self-reported discontinuation of MMT within the last six months. Multivariable Generalized Estimating Equations (GEE) were conducted to identify factors independently associated with MMT discontinuation.
Between 2005 and 2015, 1301 PWUD who had accessed MMT were recruited, among whom 288 (22.1%) discontinued MMT at least once during the study period. In multivariable GEE analyses, homelessness (Adjusted Odds Ratio [AOR] = 1.46, 95% Confidence Interval [95% CI]: 1.09-1.95), daily heroin injection (AOR = 5.17, 95% CI: 3.82-6.99), daily prescription opioid use (injection or non-injection) (AOR = 2.18, 95% CI: 1.30-3.67), recent incarceration (AOR = 1.46, 95% CI: 1.01-2.12), and not being on any form of income assistance (AOR = 2.14, 95% CI: 1.33-3.46) were each independently positively associated with MMT discontinuation. Participants with more study visits on methadone (>50% vs. ≤50% of visits) (AOR = 0.63, 95% CI: 0.47-0.85) and those with higher methadone dose (>100 mg vs. <60 mg per day) (AOR = 0.44, 95% CI: 0.31-0.62) were less likely to discontinue MMT.
Discontinuation of MMT in this urban setting was associated with recent homelessness and incarceration, not accessing social income assistance, as well as daily prescription opioid use and daily heroin injection drug use. These findings underscore a need to reduce potential barriers to MMT retention by providing access to stable housing and preventing treatment interruptions during transitions between community and custodial settings.
美沙酮维持治疗(MMT)仍然是治疗阿片类药物使用障碍的关键方法,尽管过早停止 MMT 会增加过量用药和其他严重伤害的风险。我们研究了与加拿大温哥华的一群吸毒者(PWUD)的 MMT 停药相关的社会人口特征、物质使用模式和社会结构暴露因素。
数据来自加拿大温哥华的前瞻性 PWUD 队列 VIDUS 和 ACCESS。感兴趣的结果是在过去六个月内自我报告的 MMT 停药。采用多变量广义估计方程(GEE)来确定与 MMT 停药独立相关的因素。
2005 年至 2015 年间,共招募了 1301 名接受 MMT 的 PWUD,其中 288 名(22.1%)在研究期间至少停止过一次 MMT。在多变量 GEE 分析中,无家可归(调整后的优势比[OR] = 1.46,95%置信区间[95%CI]:1.09-1.95)、每日海洛因注射(OR = 5.17,95%CI:3.82-6.99)、每日处方类阿片药物使用(注射或非注射)(OR = 2.18,95%CI:1.30-3.67)、最近监禁(OR = 1.46,95%CI:1.01-2.12)和未接受任何形式的收入援助(OR = 2.14,95%CI:1.33-3.46)与 MMT 停药独立正相关。在美沙酮治疗中接受更多治疗就诊(>50%比≤50%就诊)(OR = 0.63,95%CI:0.47-0.85)和接受更高美沙酮剂量(>100 mg 比<60 mg 每天)(OR = 0.44,95%CI:0.31-0.62)的参与者不太可能停止 MMT。
在这个城市环境中,MMT 的停药与最近的无家可归和监禁、无法获得社会收入援助以及日常处方类阿片药物使用和每日海洛因注射药物使用有关。这些发现强调需要通过提供稳定住房和防止在社区和监禁环境之间过渡期间治疗中断来减少 MMT 保留的潜在障碍。